The FDA on April 22, 2020, granted accelerated approval to TRODELVY®, for adult patients with metastatic triple-negative breast cancer, who received at least two prior therapies for metastatic disease. TRODELVY® is a product of Immunomedics, Inc.
Bottom Ad
Advertisement
Subscribe
